AKBA
Akebia Therapeutics, Inc.Company Information
- Company Name
- Akebia Therapeutics, Inc.
- CIK
- CIK0001517022
- Category
- Large accelerated filer
- Ticker: Exchange
- AKBA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AKBA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-04
- Last sale
- 2026-06-29
- Shares purchased (TTM)
- 69,270
- Shares sold (TTM)
- 745,372
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 105,588,771
- Shares outstanding
- 269,602,747
- Ownership
- 39.16%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- -31.86%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 156 | 163 | 185 | 166 | 137 | 113 | 52 | 34 | 39 | 42 | 43 | 47 | ||||||
| Inventory Net | 13 | 13 | 16 | 19 | 17 | 20 | 16 | 20 | 24 | 26 | 16 | 18 | ||||||
| Accounts Receivable Net Current | 54 | 63 | 47 | 66 | 73 | 62 | 34 | 32 | 30 | 27 | 39 | 23 | ||||||
| Prepaid Expense And Other Assets Current | 7 | 5 | 5 | 7 | 8 | 9 | 11 | 13 | 19 | 19 | 20 | 22 | ||||||
| Assets Current | 230 | 243 | 253 | 258 | 235 | 204 | 114 | 100 | 112 | 113 | 118 | 110 | ||||||
| Property Plant And Equipment Net | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | ||||||
| Operating Lease Right Of Use Asset | 6 | 2 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ||||||
| Goodwill | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | 0 | 9 | 18 | 27 | 36 | 45 | ||||||
| Other Assets Noncurrent | 54 | 57 | 60 | 40 | 44 | 38 | 37 | 27 | 18 | 12 | 12 | 4 | ||||||
| Assets | 350 | 363 | 377 | 364 | 346 | 310 | 221 | 207 | 220 | 225 | 242 | 235 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 9 | 8 | 21 | 10 | 12 | 13 | 15 | 13 | 10 | 12 | 15 | 9 | ||||||
| Accrued Liabilities Current | 110 | 125 | 122 | 106 | 92 | 71 | 63 | 52 | 54 | 54 | 68 | 63 | ||||||
| Contract With Customer Liability Current | 6 | 4 | 3 | 4 | 6 | 1 | 0 | - | 43 | 1 | 0 | 0 | ||||||
| Long Term Debt Current | 25 | 12 | - | - | - | - | 0 | 0 | 0 | 0 | 18 | 8 | ||||||
| Contract With Customer Refund Liability Current | 11 | 23 | 17 | 13 | 10 | 6 | 2 | - | - | - | 0 | - | ||||||
| Liabilities Current | 161 | 174 | 163 | 133 | 119 | 91 | 81 | 66 | 107 | 66 | 100 | 80 | ||||||
| Operating Lease Liability Noncurrent | 4 | - | 0 | 0 | 1 | 2 | 4 | 5 | 6 | 8 | 9 | 10 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 43 | 43 | 43 | ||||||
| Long Term Debt Noncurrent | 25 | 36 | 48 | 48 | 47 | 47 | 39 | 38 | 38 | 30 | 17 | 35 | ||||||
| Derivative Liabilities | - | - | - | - | - | - | - | - | - | - | 0 | 1 | ||||||
| Contract With Customer Refund Liability Noncurrent | 21 | 16 | 23 | 28 | 31 | 34 | 38 | 40 | 40 | 40 | 40 | 40 | ||||||
| Derivative Liabilities Noncurrent | 2 | 3 | 3 | 5 | 14 | 7 | 5 | 4 | 3 | 5 | 0 | - | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 2 | 5 | 5 | 5 | 5 | 5 | 7 | 7 | 9 | 9 | ||||||
| Liabilities | 325 | 335 | 344 | 323 | 316 | 286 | 270 | 258 | 254 | 253 | 272 | 274 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,727 | 1,720 | 1,716 | 1,713 | 1,701 | 1,697 | 1,629 | 1,605 | 1,602 | 1,600 | 1,578 | 1,570 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -1,702 | -1,693 | -1,684 | -1,671 | -1,672 | -1,672 | -1,678 | -1,656 | -1,636 | -1,627 | -1,609 | -1,610 | ||||||
| Stockholders Equity | 25 | 27 | 33 | 42 | 29 | 25 | -49 | -50 | -34 | -27 | -31 | -39 | ||||||
| Liabilities And Stockholders Equity | 350 | 363 | 377 | 364 | 346 | 310 | 221 | 207 | 220 | 225 | 242 | 235 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | ||||||
| Common Stock Shares Issued | 272 | 268 | 265 | 265 | 263 | 262 | 225 | 212 | 210 | 209 | 195 | 188 | ||||||
| Shares Outstanding | 272 | 268 | 265 | 265 | 263 | 262 | 225 | 212 | 210 | 209 | 195 | 188 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAkebia Therapeutics, Inc. (AKBA) — SEC Financial Statements & Analysis
Akebia Therapeutics, Inc. (AKBA) is a pharmaceutical preparations company, incorporated in DE. Akebia Therapeutics, Inc. trades on Nasdaq as: AKBA. Akebia Therapeutics, Inc. (AKBA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Akebia Therapeutics, Inc. carries a market cap of $307.35M, a P/E ratio of -10.36x, a P/B ratio of 12.29x, a P/S ratio of 1.40x, an enterprise value of $199.65M, and an EV/EBITDA multiple of -14.71x. On profitability, it posts a gross margin of 79.63%, an operating margin of -6.90%, a net margin of -13.54%, a Return on Equity (ROE) of -109.38%, and a Return on Assets (ROA) of -8.53%. Per share, it reports EPS of $-0.11, diluted EPS of $-0.11, free cash flow per share of $0.15, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 7.52% year-over-year, net income growth of -18.69% year-over-year, and EPS growth of -20.81% year-over-year. On the balance sheet, it maintains a current ratio of 1.43x, a quick ratio of 1.30x, working capital of $68.69M, a debt-to-equity ratio of 12.98x, a debt ratio of 0.93, an interest coverage ratio of -0.87x, free cash flow of $40.26M (TTM), and net debt of $-107.69M. Figures sourced from SEC EDGAR.
- Market Cap
- $307.35M
- P/E TTM
- -10.36x
- EPS TTM
- $-0.11
- P/B TTM
- 12.29x
- ROE TTM
- -109.38%
- ROA TTM
- -8.53%
- Debt To Equity
- 12.98x
- Free Cash Flow TTM
- $40.26M
- Net Revenue TTM Growth 1Y
- 7.52%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Akebia Therapeutics, Inc. in?
Akebia Therapeutics, Inc. (AKBA) operates in the Pharmaceutical Preparations industry.
What exchange does AKBA trade on?
Akebia Therapeutics, Inc. (AKBA) trades on the Nasdaq.
Where is Akebia Therapeutics, Inc. incorporated?
Akebia Therapeutics, Inc. is incorporated in DE.
When was Akebia Therapeutics, Inc. (AKBA)'s most recent SEC filing?
Akebia Therapeutics, Inc. (AKBA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is AKBA's market cap?
Akebia Therapeutics, Inc. (AKBA) has a market capitalization of $307.35M as of 2026-06-30.
What is AKBA's EPS (earnings per share)?
Akebia Therapeutics, Inc. (AKBA)'s trailing twelve month EPS is $-0.11 as of 2026-06-30.
What is AKBA's ROE (return on equity)?
Akebia Therapeutics, Inc. (AKBA)'s trailing twelve month Return on Equity (ROE) is -109.38% as of 2026-06-30.
What is AKBA's ROA (return on assets)?
Akebia Therapeutics, Inc. (AKBA)'s trailing twelve month Return on Assets (ROA) is -8.53% as of 2026-06-30.
What is AKBA's EV/EBITDA?
Akebia Therapeutics, Inc. (AKBA)'s trailing twelve month EV/EBITDA is -14.71x as of 2026-06-30.